Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1954 2
1956 1
1957 1
1958 2
1959 1
1961 2
1962 4
1963 3
1964 5
1965 3
1966 1
1967 3
1968 3
1969 7
1970 8
1971 2
1972 9
1973 3
1974 10
1975 9
1976 20
1977 20
1978 12
1979 23
1980 37
1981 21
1982 25
1983 21
1984 40
1985 45
1986 54
1987 34
1988 57
1989 52
1990 55
1991 63
1992 52
1993 64
1994 60
1995 79
1996 80
1997 69
1998 52
1999 68
2000 68
2001 85
2002 74
2003 86
2004 76
2005 91
2006 97
2007 86
2008 99
2009 92
2010 96
2011 98
2012 108
2013 89
2014 96
2015 105
2016 102
2017 101
2018 70
2019 76
2020 92
2021 88
2022 85
2023 70
2024 77
2025 38

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,200 results

Results by year

Filters applied: . Clear all
Page 1
The past, present, and future of immunotherapy for endometrial adenocarcinoma.
Jones AC, Brown KH, Guan T, Smith LA, Formslag CR, Farjado ED, Bai Q, Luechtefeld HD, Wakefield MR, Dong L, Fang Y. Jones AC, et al. Med Oncol. 2023 May 23;40(7):186. doi: 10.1007/s12032-023-02040-7. Med Oncol. 2023. PMID: 37219649 Review.
Incidences of endometrial adenocarcinoma are increasing in the USA with poor prognosis for patients with advanced disease. ...This study could be helpful for clinicians to identify treatment options more suitable for women with late-stage endometrial adeno …
Incidences of endometrial adenocarcinoma are increasing in the USA with poor prognosis for patients with advanced disease. ... …
Endometrial adenocarcinoma metastatic to the pituitary gland: a case report and literature review.
Du H, Jia A, Ren Y, Gu M, Li H, Sun M, Tang T, Liu H, Bai J. Du H, et al. J Int Med Res. 2020 Jun;48(6):300060520924512. doi: 10.1177/0300060520924512. J Int Med Res. 2020. PMID: 32500767 Free PMC article. Review.
Pituitary metastases are rare, and metastatic pituitary lesions originating from endometrial adenocarcinoma are extremely rare. These lesions can be mistaken for pituitary adenomas and their diagnosis can be very difficult. ...A 68-year-old woman who was being follo …
Pituitary metastases are rare, and metastatic pituitary lesions originating from endometrial adenocarcinoma are extremely rare …
Metastasis of endometrial adenocarcinoma masquerading as a primary rectal cancer: A rare case report with literature review.
Li M, Zheng W. Li M, et al. Medicine (Baltimore). 2023 Nov 17;102(46):e36170. doi: 10.1097/MD.0000000000036170. Medicine (Baltimore). 2023. PMID: 37986305 Free PMC article. Review.
PATIENT CONCERNS: Herein we present a rare case of a 68-year-old postmenopausal woman with a history of endometrial adenocarcinoma, metastasizing to the rectum 5 years after a hysterectomy and bilateral salpingo-oophorectomy treatments with pelvic lymphadenectomy we …
PATIENT CONCERNS: Herein we present a rare case of a 68-year-old postmenopausal woman with a history of endometrial adenocarcinoma …
CXCR3 predicts the prognosis of endometrial adenocarcinoma.
Dong H, Sun M, Li H, Yue Y. Dong H, et al. BMC Med Genomics. 2023 Feb 7;16(1):20. doi: 10.1186/s12920-023-01451-9. BMC Med Genomics. 2023. PMID: 36750966 Free PMC article.
OBJECTIVES: Currently, endometrial adenocarcinoma lacks an effective prognostic indicator. This study was to develop and validate a gene biomarker and a nomogram to predict the survival of endometrial adenocarcinoma, explore potential mechanisms and se …
OBJECTIVES: Currently, endometrial adenocarcinoma lacks an effective prognostic indicator. This study was to develop and valid …
Inflammatory events in endometrial adenocarcinoma.
Wallace AE, Gibson DA, Saunders PT, Jabbour HN. Wallace AE, et al. J Endocrinol. 2010 Aug;206(2):141-57. doi: 10.1677/JOE-10-0072. Epub 2010 Apr 20. J Endocrinol. 2010. PMID: 20406782 Review.
Endometrial adenocarcinoma is the most common gynaecological malignancy in western countries. ...This review discusses the contribution of inflammation to the initiation and progression of endometrial adenocarcinoma. Manipulation of inflammatory pathwa …
Endometrial adenocarcinoma is the most common gynaecological malignancy in western countries. ...This review discusses the con …
ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL.
Ma X, Xia M, Wei L, Guo K, Sun R, Liu Y, Qiu C, Jiang J. Ma X, et al. Cell Death Dis. 2022 Dec 23;13(12):1067. doi: 10.1038/s41419-022-05507-z. Cell Death Dis. 2022. PMID: 36550099 Free PMC article.
In this study, we first found MGLL was highly expressed in progesterone resistant samples of endometrial adenocarcinoma, and then we verified its expression was increased in endometrial adenocarcinoma. ...Targeted inhibition of MGLL by inhibitors may b …
In this study, we first found MGLL was highly expressed in progesterone resistant samples of endometrial adenocarcinoma, and t …
Endometrial adenocarcinoma with bone metastasis: A case report.
Mirzaei M, Eshraghi A, Ghoddoosi M, Fatemi MA, Eshraghi A, Suvvari TK, Fazilat-Panah D. Mirzaei M, et al. Clin Case Rep. 2022 May 9;10(5):e05836. doi: 10.1002/ccr3.5836. eCollection 2022 May. Clin Case Rep. 2022. PMID: 35582164 Free PMC article.
We reported a female with endometrial adenocarcinoma who was evaluated with whole-body bone scan for new-onset bone pains 6 months after completion of treatment....
We reported a female with endometrial adenocarcinoma who was evaluated with whole-body bone scan for new-onset bone pains 6 mo …
Endometrial adenocarcinoma: a primer for the generalist.
Hernandez E. Hernandez E. Obstet Gynecol Clin North Am. 2001 Dec;28(4):743-57. doi: 10.1016/s0889-8545(05)70233-3. Obstet Gynecol Clin North Am. 2001. PMID: 11766149 Review.
The mean and median age of women with endometrial adenocarcinoma is 61 years. Most endometrial cancers are type I estrogen-dependent endometrioid adenocarcinomas. Most women with endometrial adenocarcinoma have stage I disease. Patients with stage I di …
The mean and median age of women with endometrial adenocarcinoma is 61 years. Most endometrial cancers are type I estrogen-dep …
The importance of hCG in human endometrial adenocarcinoma and breast cancer.
Kölbl AC, Schlenk K, Behrendt N, Andergassen U. Kölbl AC, et al. Int J Biol Markers. 2018 Jan;33(1):33-39. doi: 10.5301/ijbm.5000290. Int J Biol Markers. 2018. PMID: 28967068 Free article. Review.
But its impact is not limited to pregnancy; it also influences tumor formation and metastatic outgrowth, especially in endometrial adenocarcinoma and breast cancer. This review summarizes what has been written in the literature about the role of hCG as a tumor marke …
But its impact is not limited to pregnancy; it also influences tumor formation and metastatic outgrowth, especially in endometrial …
Endometrial Adenocarcinoma, Endometrioid Type.
Erickson LA. Erickson LA. Mayo Clin Proc. 2018 Jul;93(7):963-964. doi: 10.1016/j.mayocp.2018.03.017. Mayo Clin Proc. 2018. PMID: 29976383 No abstract available.
3,200 results